Candidate genes associated with malignant pheochromocytomas by genome-wide expression profiling

Annals of Surgery

Volumn 250, Issue 6, 2009, Pages 983-990

  Suh, Insoo ^a   Shibru, Daniel ^a   Eisenhofer, Graeme ^b   Pacak, Karel ^c   Duh, Quan Yang ^a   Clark, Orlo H ^a,d   Kebebew, Electron ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUB1 RELATED PROTEIN; CXCL11 CHEMOKINE; CYCLIN DEPENDENT KINASE 1; EXCITATORY AMINO ACID TRANSPORTER 4; PROTEIN HOMER 1; SECURIN;

ADAMTS GENE; ADULT; ARTICLE; BENIGN TUMOR; CARCINOGENESIS; CELL DEDIFFERENTIATION; CFC1 GENE; DIAGNOSTIC ACCURACY; ELECTRON TRANSPORT; FAM62B GENE; FEMALE; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; ION TRANSPORT; LRRN3 GENE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MICROARRAY ANALYSIS; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PROTEIN TRANSPORT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTION; TBX3 GENE;

ADRENAL GLAND NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHEOCHROMOCYTOMA; POLYMERASE CHAIN REACTION; RNA, NEOPLASM; ROC CURVE; TIME FACTORS;

EID: 73449104566     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181b248bb     Document Type: Article

References (33)

1. Kebebew E, Duh QY. Benign and malignant pheochromocytoma: diagnosis, treatment, and follow-up. Surg Oncol Clin N Am. 1998;7:765-789.
2. Bryant J, Farmer J, Kessler LJ, et al. Pheochromocytoma: the expanding genetic differential diagnosis. J Natl Cancer Inst. 2003;95:1196-1204.
3. Koch CA, Pacak K, Chrousos GP. The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors. J Clin Endocrinol Metab. 2002;87:5367-5384.
4. Neumann HP, Cybulla M, Shibata H, et al. New genetic causes of pheochro-mocytoma: current concepts and the clinical relevance. Keio J Med. 2005; 54:15-21.
5. Elder EE, Elder G, Larsson C. Pheochromocytoma and functional paragan-glioma syndrome: no longer the 10% tumor. J Surg Oncol. 2005;89:193-201.
6. O'Riordain DS, Young WF Jr, Grant CS, et al. Clinical spectrum and outcome of functional extraadrenal paraganglioma. World J Surg. 1996;20: 916-921; discussion 922.
7. Brouwers FM, Elkahloun AG, Munson PJ, et al. Gene expression profiling of benign and malignant pheochromocytoma. Ann NY Acad Sci. 2006;1073:541-556.
8. Timmers HJ, Kozupa A, Eisenhofer G, et al. Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succi-nate dehydrogenase subunit B-associated pheochromocytomas and paragan-gliomas. J Clin Endocrinol Metab. 2007;92:779-786.
9. Ginzinger DG. Gene quantification using real-time quantitative PCR: an emerging technology hits the mainstream. Exp Hematol. 2002;30:503-512.
10. Irizarry RA, Bolstad BM, Collin F, et al. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003;31:e15.
11. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5:R80.
12. Bolstad BM, Irizarry RA, Astrand M, et al. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003;19:185-193.
13. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3:Article 3.
14. Benjamini Y, Drai D, Elmer G, et al. Controlling the false discovery rate in behavior genetics research. Behav Brain Res. 2001;125:279-284.
15. Beissbarth T, Speed TP. GOstat: find statistically overrepresented Gene Ontologies within a group of genes (Available at: http://gostat.wehi.edu.au). Bioinformatics. 2004;20:1464-1465.
16. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545-15550.
17. Subramanian A, Kuehn H, Gould J, et al. GSEA-P: a desktop application for Gene Set Enrichment Analysis. Bioinformatics. 2007;23:3251-3253.
18. Anouar Y, Yon L, Guillemot J, et al. Development of novel tools for the diagnosis and prognosis of pheochromocytoma using peptide marker immu-noassay and gene expression profiling approaches. Ann NY Acad Sci. 2006; 1073:533-540.
19. August C, August K, Schroeder S, et al. CGH and CD 44/MIB-1 immuno-histochemistry are helpful to distinguish metastasized from nonmetastasized sporadic pheochromocytomas. Mod Pathol. 2004;17:1119-1128.
20. Boltze C, Mundschenk J, Unger N, et al. Expression profile of the telomeric complex discriminates between benign and malignant pheochromocytoma. J Clin Endocrinol Metab. 2003;88:4280-4286.
21. Jarbo C, Buckley PG, Piotrowski A, et al. Detailed assessment of chromosome 22 aberrations in sporadic pheochromocytoma using array-CGH. Int J Cancer. 2006;118:1159-1164.
22. Thouennon E, Elkahloun AG, Guillemot J, et al. Identification of potential gene markers and insights into the pathophysiology of pheochromocytoma malignancy. J Clin Endocrinol Metab. 2007;92:4865-4872.
23. Gilmore TD, Kalaitzidis D, Liang MC, et al. The c-Rel transcription factor and B-cell proliferation: a deal with the devil. Oncogene. 2004;23:2275-2286.
24. Naruganahalli KS, Lakshmanan M, Dastidar SG, et al. Therapeutic potential of Aurora kinase inhibitors in cancer. Curr Opin Investig Drugs. 2006;7: 1044-1051.
25. Lindberg D, Akerstrom G, Westin G. Mutational analyses of WNT7A and HDAC11 as candidate tumour suppressor genes in sporadic malignant pancreatic endocrine tumours. Clin Endocrinol (Oxf). 2007;66:110-114.
26. Vaque JP, Fernandez-Garcia B, Garcia-Sanz P, et al. c-Myc inhibits Ras-mediated differentiation of pheochromocytoma cells by blocking c-Jun up-regulation. Mol Cancer Res. 2008;6:325-339.
27. Wang DG, Johnston CF, Marley JJ, et al. Expression of the apoptosis-suppressing gene BCL-2 in pheochromocytoma is associated with the expression of C-MYC. J Clin Endocrinol Metab. 1997;82:1949-1952.
28. Erhardt JA, Pittman RN. Ectopic p21(WAF1) expression induces differentiation-specific cell cycle changes in PC12 cells characteristic of nerve growth factor treatment. J Biol Chem. 1998;273:23517-23523.
29. Carnero A, Blanco-Aparicio C, Renner O, et al. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets. 2008;8:187-198.
30. Horiguchi K, Hanada T, Fukui Y, et al. Transport of PIP3 by GAKIN, a kinesin-3 family protein, regulates neuronal cell polarity. J Cell Biol. 2006; 174:425-436.
31. Matsumoto K, Kagoshima M, Nakamura T. Hepatocyte growth factor as a potent survival factor for rat pheochromocytoma PC12 cells. Exp Cell Res. 1995;220:71-78.
32. Scheibe RJ, Ginty DD, Wagner JA. Retinoic acid stimulates the differentiation of PC12 cells that are deficient in cAMP-dependent protein kinase. J Cell Biol. 1991;113:1173-1182.
33. Adler JT, Hottinger DG, Kunnimalaiyaan M, et al. Histone deacetylase inhibitors upregulate Notch-1 and inhibit growth in pheochromocytoma cells. Surgery. 2008;144:956-961; discussion 961-962.